PROGENICS SOLUBLE CD4 PHASE I STUDIES
PROGENICS SOLUBLE CD4 PHASE I STUDIES are slated to begin "within the next 12 to 18 months," according to the firm. Progenics said it is one of four companies to license patent rights of recombinant soluble CD4 from Columbia University. Also included in the "co-exclusive" patent agreement are Genentech, Biogen and SmithKline. The patent application for CD4, filed August 1986 on behalf of Columbia University, is still pending. Progenics plans to study the drug in 50-100 patients with Columbia University investigators at several university-affiliated hospitals. The Tarrytown, NY-based company has begun manufacturing CD4 in quantities needed for the clinical trial. In the area of research, the firm "is also working on several novel approaches for targeting and destroying the AIDS virus directly," a March 27 release notes. The license agreement includes "U.S. and foreign patent applications relating to current versions of soluble CD4 [now in separate clinical trials] as well as future CD4-based AIDS drugs," the company states, adding: "The license [also] concerns CD4 fragments, alone or linked to other molecules, which are capable of binding to the AIDS virus." Genentech was the first company to enter clinical trials with CD4 last summer and is developing a second generation CD4 product that links the soluble T4 receptor to immunoglobin G. Biogen began CD4 studies last fall and reports it is also developing a second generation CD4 product. The most recent entrant in the CD4 race is SmithKline, whose Treatment IND was approved in January. Results from these first generation CD4 safety studies are expected to be presented at the International AIDS Conference to be held in Montreal in early June ("The Pink Sheet" March 6, T&G-5).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth